Vanguard Group’s Mustang Bio MBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $56.8K | Hold |
57,863
| – | – | ﹤0.01% | 4228 |
|
|
2025
Q3 | $88K | Buy |
+57,863
| New | +$103K | ﹤0.01% | 4241 |
|
|
2025
Q1 | – | Sell |
-1,508
| Closed | -$13.3K | – | 4297 |
|
|
2024
Q4 | $13.3K | Hold |
1,508
| – | – | ﹤0.01% | 4276 |
|
|
2024
Q3 | $17.7K | Hold |
1,508
| – | – | ﹤0.01% | 4309 |
|
|
2024
Q2 | $35.7K | Sell |
1,508
-2,606
| -63% | -$49.5K | ﹤0.01% | 4314 |
|
|
2024
Q1 | $214K | Buy |
4,114
+523
| +15% | +$33.2K | ﹤0.01% | 4167 |
|
|
2023
Q4 | $242K | Buy |
3,591
+39
| +1% | +$3.1K | ﹤0.01% | 4191 |
|
|
2023
Q3 | $368K | Hold |
3,552
| – | – | ﹤0.01% | 4143 |
|
|
2023
Q2 | $1.1M | Hold |
3,552
| – | – | ﹤0.01% | 3867 |
|
|
2023
Q1 | $977K | Hold |
3,552
| – | – | ﹤0.01% | 3926 |
|
|
2022
Q4 | $1.05M | Sell |
3,552
-4
| -0.1% | -$1.37K | ﹤0.01% | 3899 |
|
|
2022
Q3 | $1.25M | Buy |
3,556
+643
| +22% | +$298K | ﹤0.01% | 3933 |
|
|
2022
Q2 | $1.28M | Sell |
2,913
-1,064
| -27% | -$589K | ﹤0.01% | 4003 |
|
|
2022
Q1 | $3.01M | Sell |
3,977
-1,981
| -33% | -$1.63M | ﹤0.01% | 3777 |
|
|
2021
Q4 | $7.42M | Sell |
5,958
-57
| -0.9% | -$92K | ﹤0.01% | 3397 |
|
|
2021
Q3 | $12.1M | Buy |
6,015
+34
| +0.6% | +$73K | ﹤0.01% | 3134 |
|
|
2021
Q2 | $14.9M | Buy |
5,981
+2,016
| +51% | +$4.94M | ﹤0.01% | 2999 |
|
|
2021
Q1 | $9.87M | Buy |
3,965
+1,080
| +37% | +$3.21M | ﹤0.01% | 3153 |
|
|
2020
Q4 | $8.19M | Buy |
2,885
+804
| +39% | +$1.92M | ﹤0.01% | 3095 |
|
|
2020
Q3 | $4.92M | Sell |
2,081
-24
| -1% | -$59.2K | ﹤0.01% | 3154 |
|
|
2020
Q2 | $5.02M | Buy |
2,105
+262
| +14% | +$613K | ﹤0.01% | 3098 |
|
|
2020
Q1 | $3.7M | Buy |
1,843
+2
| +0.1% | +$5.13K | ﹤0.01% | 3101 |
|
|
2019
Q4 | $5.63M | Sell |
1,841
-9
| -0.5% | -$20.6K | ﹤0.01% | 3132 |
|
|
2019
Q3 | $4.52M | Sell |
1,850
-320
| -15% | -$875K | ﹤0.01% | 3173 |
|
|
2019
Q2 | $5.99M | Buy |
2,170
+1,618
| +293% | +$4.62M | ﹤0.01% | 3104 |
|
|
2019
Q1 | $1.41M | Buy |
552
+37
| +7% | +$105K | ﹤0.01% | 3544 |
|
|
2018
Q4 | $1.14M | Sell |
515
-355
| -41% | -$1.08M | ﹤0.01% | 3531 |
|
|
2018
Q3 | $3.88M | Sell |
870
-4
| -0.5% | -$20K | ﹤0.01% | 3322 |
|
|
2018
Q2 | $4.52M | Buy |
874
+86
| +11% | +$543K | ﹤0.01% | 3243 |
|
|
2018
Q1 | $6.46M | Buy |
788
+36
| +5% | +$307K | ﹤0.01% | 3039 |
|
|
2017
Q4 | $6.76M | Buy |
+752
| New | +$5.82M | ﹤0.01% | 3008 |
|
Other funds holding MBIO
KAS
DS
XT
GCP
CG
Vanguard Group's MBIO Position: Q4 2025 in Review
Vanguard Group held its Mustang Bio (MBIO) position steady in Q4 2025 at 57,863 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4228.
Vanguard Group first reported a position in MBIO in Q4 2017 and has held it in 31 quarters since. The position peaked at $14.9M in Q2 2021. 25 funds tracked by Wall St. Rank hold MBIO as of Q4 2025.
- Vanguard Group held 57,863 shares of Mustang Bio worth $56.8K as of Q4 2025.
- Vanguard Group left its Mustang Bio share count unchanged in Q4 2025.
- Mustang Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4228 holding.
- Vanguard Group first reported a position in Mustang Bio in Q4 2017 and has held it in 31 quarters since.
- Vanguard Group's Mustang Bio position peaked at $14.9M in Q2 2021.
- 25 funds tracked by Wall St. Rank held Mustang Bio as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.